Start here if you're new
what it is
It moves donor organs, coordinates recovery teams, and provides perfusion services when hospitals are out of time.
how it gets paid
Last year Strata Critical Med made $197M in revenue. Air and ground logistics was the main engine at $88.7M, or 45% of sales.
why it's growing
Revenue grew 34.3% last year. The quarter was driven by strong logistics demand.
what just happened
Q4 2025 revenue hit $66.8M, up 83.5% vs. prior year, but EPS landed at -$0.04.
At a glance
B balance sheet — gets the job done, barely
-$0.35 fy2024 eps est
$2B fy2026 rev est
11.3% operating margin
1.65 beta
xvary composite: 55/100 — below average
What they do
It moves donor organs, coordinates recovery teams, and provides perfusion services when hospitals are out of time.
When a transplant team needs an organ moved now, you do not open five tabs and compare prices. You call the operator that can move the organ, staff the recovery, and coordinate the handoff in one shot; Strata does that with a national network and 310 employees. That bundled setup is switching costs → changing vendors is risky and slow → customers stick with the one already inside the workflow.
How they make money
$197M
annual revenue · their business grew +34.3% last year
Air and ground logistics
$88.7M
+35.3%
Surgical organ recovery
$47.3M
+34.3%
Organ placement and NRP
$35.5M
+34.3%
Perfusion staffing
$15.8M
+34.3%
Perfusion equipment solutions
$9.7M
+34.3%
The products that matter
urgent medical transport
Time-Critical Logistics
$~158M · ~80% of revenue
this is the core business at roughly $158M of the company’s $197M revenue base, and it delivered 35.3% growth in the latest quarter.
growth engine
organ procurement services
Surgical Organ Recovery
part of ~$39M segment
it sits inside the medical services segment, which makes up about 20% of revenue, and it helped support q4 gross margin improving to 21.5% from 20.8%.
margin support
recipient matching workflow
Organ Placement
revenue not disclosed
the company does not break out revenue here, so you should treat it as part of the broader $39M medical services bucket rather than a standalone growth pillar.
data thin
Key numbers
34.3%
revenue growth
Sales grew 34.3% vs. prior year to $197M. Plain English: demand is rising fast enough to matter.
11.3%
operating margin
Operating margin means profit after running the business. Plain English: Strata is still losing money on the core operation.
$3M
long-term debt
Long-term debt is just $3M, or 1% of capital. Plain English: balance-sheet stress is low while management tries to scale.
1.65
beta
Beta measures how violently a stock moves versus the market. Plain English: this name tends to swing harder than your index fund.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $3M (1% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SRTA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Q4 2025 revenue hit $66.8M, up 83.5% vs. prior year, but EPS landed at -$0.04.
The quarter was driven by strong logistics demand, with logistics revenue and gross profit up 35.3% and 39.5%, respectively. Gross margin improved to 21.5% from 20.8% a year earlier, but earnings still came in below the -$0.01 figure cited ahead of the report.
$66.8M
revenue
$0.04
eps
21.5%
gross margin
the number that mattered
The 21.5% gross margin mattered most because every 1-point margin gain on $197M of annual revenue is about $2.0M in extra gross profit.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is failing to justify the new $260–$275M revenue target after one explosive quarter.
med
guidance reset risk
last year’s revenue was $197M. the new $260–$275M target implies roughly 32–40% growth. if that pace slips, the 21% post-earnings surge starts to look like borrowed time.
last year’s revenue was $197M. the new $260–$275M target implies roughly 32–40% growth. if that pace slips, the 21% post-earnings surge starts to look like borrowed time.
med
thin margin cushion
gross margin improved to 21.5% from 20.8%, which is progress but not protection. this is still a business where execution has to stay clean because the margin buffer is modest.
gross margin improved to 21.5% from 20.8%, which is progress but not protection. this is still a business where execution has to stay clean because the margin buffer is modest.
low
limited segment disclosure
medical services is roughly $39M of revenue, but the company does not break out products like organ placement cleanly. when disclosure is thin, surprises travel faster.
medical services is roughly $39M of revenue, but the company does not break out products like organ placement cleanly. when disclosure is thin, surprises travel faster.
the combined setup is simple: investors are paying for acceleration. from a $197M base, management now has to deliver a $260–$275M year while keeping gross margin at least stable.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next earnings report
may 12, 2026 is the first real check after the guidance raise. one quarter started this rerating. the next one has to support it.
metric
pace toward the 2026 target
$260–$275M against last year’s $197M means roughly 32–40% growth. that is the bar now, not the stretch goal.
trend
organic logistics growth
35% organic growth in logistics was the cleanest signal in the quarter. if that cools fast, the growth story gets a lot less clean.
risk
gross margin durability
gross margin reached 21.5%, up from 20.8%. improvement matters, but you still do not have a lot of room for operational slippage.
Analyst rankings
risk profile
above average
risk rank 2 — safer than roughly 80% of stocks.
chart momentum
below average
momentum rank 4 — analysts see underperformance risk in the near term.
source: institutional data
Institutional activity
institutional ownership data for SRTA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive